Jetoptera and Eanan J500 VTOL Cargo UAS Turbocompressor Map Testing Campaign
At the core of the J-500 is Jetoptera's proprietary Fluidic Propulsive System™ (FPS™), powered by a 250 kW turbocompressor developed by the USA based company, Jetoptera. This innovative propulsion architecture offers a modular and scalable solution designed for reduced noise, enhanced safety, and unmatched mission versatility.
The First Engine to Test (FETT) was immediately followed by the Second Engine test campaign hosted by EANAN at its facilities in the UAE. The turbocompressor mapping is a critical step to validate the operability of this innovative modular propulsion system. The two-stage axial compressor driven by a free turbine is being tested for safe operability throughout the mission, from take-off to cruise to loitering, to vertical landing.
'The state-of-the-art setup that EANAN and Jetoptera have built is heavily instrumented to accurately characterize the efficiencies and operability of the heart of the FPS™,' said Dr. Andrei Evulet, Jetoptera CEO and former Technology Maturation and Integration Leader at GE Aerospace, where he led the successful test campaign of the GE9X High Pressure Compressor. 'In the first weeks of testing we obtained results that demonstrate operability of the compressor model design and support our plan to deliver the propulsion system for the J-500 as planned.'
Two units are currently mapped; the results so far are promising. The Free Turbine Compressor (FTC-250) represents an unprecedented modularity in design, with the gas generator, FTC and FPS™ subsystems being able to operate in FPS™ configurations for V/STOL and low noise mission stages, as turbofan, bypassing the FPS™ for a dedicated nozzle for highest-speed mission stages. The gas generator itself can be used as a turbojet with the addition of a simple convergent nozzle. The Specific Fuel Consumption (SFC) decreases from the turbojet mode (which is the simplest and lightest application for conventional flight) to turbofan and finally to the FPS™, with targeted SFC 2-3 times lower than the turbojet's mode.
The campaign also furthers the design of the controls of the aircraft. Unlike common UAVs that rely on rotors and propellers, the J-500 leverages a pneumatic system to distribute compressed air through dynamically actuated valves to the FPS™ thrusters, enabling precise control of the aircraft's attitude and maneuvering.
Ulrich Weckx, CEO of EANAN, emphasized the significance of this partnership:
'The J-500 is a symbol of what can be achieved when innovation meets execution. Our collaboration with Jetoptera allows us to jointly develop a revolutionary propulsion-integrated airframe that leverages Jetoptera's unique FPS™ technology, while benefiting from EANAN's testing infrastructure in the UAE. This test campaign is not only a technical success; it's a strategic step forward in our shared vision to redefine advanced air mobility'.
For information about this press release please contact Todd Newton
todd@jetoptera.com
Jetoptera, Inc.
https://www.jetoptera.com
Facebook:
https://www.facebook.com/Jetoptera/
Linkedin:
https://www.linkedin.com/company/jetoptera/posts/?feedView=all
Photos accompanying this announcement are available at:
https://www.globenewswire.com/NewsRoom/AttachmentNg/34ae26f6-2244-490e-a6e8-e0fe3292479f
https://www.globenewswire.com/NewsRoom/AttachmentNg/eae4e748-2ca1-4d85-a65f-73c9131b227e
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
39 minutes ago
- Business Wire
MaaT Pharma Secures €37.5 Million Loan From European Investment Bank (EIB) Marking a New Step in Advancing its Clinical Program in Hemato-Oncology
LYON, France--(BUSINESS WIRE)--Regulatory News: We are grateful for the confidence shown in MaaT Pharma and the support from the EIB, which is a further foundation towards the next phase of MaaT Pharma's growth on bringing the potential first microbiome-based therapy to market in Europe. MaaT Pharma (EURONEXT: MAAT – the 'Company'), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem Therapies™ (MET) dedicated to enhancing survival for patients with cancer through immune modulation, today announced that it has secured a €37.5 million, 4-tranche financing from the European Investment Bank (EIB). The financing will support the advancement of its late-stage hemato-oncology clinical programs including the lead-asset Xervyteg ®, recently partnered with Clinigen in Europe, and currently under regulatory review by the European Medicines Agency (EMA) for the treatment of acute Graft-versus-Host Disease (aGvHD) and the second drug candidate, MaaT033, currently being evaluated in a Phase 2b randomized controlled trial in improving survival for patients receiving allogeneic stem cell transplants. With robust cGMP manufacturing, proprietary therapies, and a development platform, MaaT Pharma is a global leader in microbiome-based oncology, pioneering full-ecosystem therapies to improve survival in oncology. Since completing enrollment in the ARES trial for Xervyteg ® (MaaT013) in October 2024, MaaT Pharma has steadily advanced its roadmap, reporting topline results in January 2025, submitting the Marketing Authorization Application with the European Medicines Agency in June 2025, and signing an exclusive agreement for marketing and distribution in Europe with Clinigen in July 2025. The €37.5 million financing from the EIB follows a rigorous due diligence process by the EIB and further confirms MaaT Pharma's innovation, strategic vision and operational maturity. This funding is part of a global financial strategy to support the Company's development that combines various non-dilutive and dilutive sources to best preserve shareholder value. Eric Soyer, Chief Financial Officer, MaaT Pharma, said: 'We are grateful for the confidence shown in MaaT Pharma and the support from the EIB, which is a further foundation towards the next phase of MaaT Pharma's growth on bringing the potential first microbiome-based therapy to market in Europe. Each operational and financing step strengthens our track record. Following the regulatory submission to the EMA for Xervyteg ® (MaaT013) and our recent partnership with Clinigen for its commercialization, the EIB financing represents another step in reinforcing the Company's financial position. As previously announced, MaaT Pharma intends to fund its plans and development programs while preserving shareholder value in the best manner possible with a mix of non-dilutive and dilutive financial sources, and the recent announcements of both partnership financing with the Clinigen agreement and debt financing with the EIB agreement, are benchmarks to reflect that strategy.' Summary of the main terms and conditions of the Loan and Warrants The loan would be available in four (4) tranches, respectively of €3.5 million for Tranche A, €6.0 million for Tranche B, €8.0 million for Tranche C, and €20.0 million for Tranche D, each tranche with Warrants attached. Disbursement of Tranches 2 to 4 are subject to operational and financing conditions. All Tranches are redeemable after a grace period of 4 years from the date of drawing, with reimbursement over a period of 2 years (Tranche A, B and C, i.e. a maturity of 6 years) to 4 years (Tranche D, i.e. a maturity of 8 years). Each tranche will bear interests at 7%, it being provided that some interests will be deferred and paid at maturity and for Tranche C and Tranche D part of the interest will be paid quarterly. MaaT Pharma will issue warrants to the benefit of EIB at the time of (and subject to) disbursement of each tranche in a number depending, for each relevant tranche, on the amount of the relevant tranche and the average price per share paid by investors in the context of equity injection made prior to disbursement of the relevant tranche (except for tranche A where the average price per share over the last trading days preceding the date of execution of the financing agreement). Each warrant will give right to subscribe to one share at a price per warrant equal to 99% of the average price over a period of 5 trading days preceding the issuance of each Warrant. The Warrants may be exercised at any time following maturity of Tranche A. The Warrants will have a 20-year term. EIB and MaaT Pharma have also agreed on (i) a put option to the benefit of EIB under which MaaT Pharma undertook to acquire from EIB all or part of the Warrants upon occurrence of certain events and (ii) a call option to the benefit of MaaT Pharma under which EIB undertook to sell all its Warrants, upon occurrence of a public tender offer over the securities issued by MaaT Pharma. The Warrants are not transferable, except to affiliates of EIB or except in case of occurrence of certain events (including maturity date of Tranche D). In case of transfer of Warrants to third party, MaaT Pharma shall benefit from a preemptive right to acquire the Warrants first. MaaT Pharma was assisted in this transaction by Mr. Eric Briole and by Van Lanschot Kempen as Financial Advisors and McDermott Will & Emery as Legal Advisor. About EIB The European Investment Bank (EIB), whose shareholders are the Member States of the European Union (EU), is the EU's long-term financing institution. Across eight major priorities, we support investments in climate action and the environment, digital transition and technological innovation, security and defense, cohesion, agriculture and the bioeconomy, social infrastructure, capital markets union, and a stronger Europe in a more peaceful and prosperous world. In 2024, the EIB Group, which also includes the European Investment Fund (EIF), signed nearly €89 billion in new financing in support of more than 900 projects in Europe and worldwide. In France, the EIB Group signed over a hundred operations in 2024 for a total amount of €12.6 billion. Nearly 60% of the EIB Group's annual financing supports projects contributing to climate change mitigation and adaptation, as well as the creation of a healthier environment. About MaaT Pharma MaaT Pharma is a leading, late-stage clinical company focused on developing innovative gut microbiome-driven therapies to modulate the immune system and enhance cancer patient survival. Supported by a talented team committed to making a difference for patients worldwide, the Company was founded in 2014 and is based in Lyon, France. As a pioneer, MaaT Pharma is leading the way in bringing the first microbiome-driven immunomodulator in oncology. Using its proprietary pooling and co-cultivation technologies, MaaT Pharma develops high diversity, standardized drug candidates, aiming at extending life of cancer patients. MaaT Pharma has been listed on Euronext Paris (ticker: MAAT) since 2021. Forward-looking Statements All statements other than statements of historical fact included in this press release about future events are subject to (i) change without notice and (ii) factors beyond the Company's control. These statements may include, without limitation, any statements preceded by, followed by, or including words such as 'target,' 'believe,' 'expect,' 'aim', 'intend,' 'may,' 'anticipate,' 'estimate,' 'plan,' 'project,' 'will,' 'can have,' 'likely,' 'should,' 'would,' 'could' and other words and terms of similar meaning or the negative thereof. Forward-looking statements are subject to inherent risks and uncertainties beyond the Company's control that could cause the Company's actual results or performance to be materially different from the expected results or performance expressed or implied by such forward-looking statements.
Business Upturn
5 hours ago
- Business Upturn
Former CIA Insider Highlights America's Buried Advantage in Online Presentation
By GlobeNewswire Published on July 28, 2025, 02:00 IST Washington, D.C., July 27, 2025 (GLOBE NEWSWIRE) — Rediscovering America's Strategic Core In a released presentation , renowned former national security advisor Jim Rickards warns that the next major shift in U.S. policy may come not from Wall Street or Washington—but from beneath the surface of federally controlled lands. 'This story is not about real estate… the government retained the most valuable part'. Rickards points to a dormant but active legal provision—originally designed to encourage domestic growth—which may now hold the key to America's technological future. The Invisible Wiring of Modern Power The materials Rickards identifies are not commodities in the traditional sense—they are foundational enablers of global advancement: Application Mineral Inputs AI Chips & Data Centers Silicon, gallium, germanium, copper EV Batteries Lithium, cobalt, nickel, manganese, graphite Missile Systems & Drones Neodymium, dysprosium, samarium, rare earth alloys Satellite Navigation Indium, tantalum, beryllium, aluminum 'These seemingly obscure minerals… they're the building blocks of everything from NVIDIA chips to advanced military weapons'. Sources: U.S. Department of Energy CSIS Visual Capitalist A 150-Year-Old Law, Still in Effect Rickards centers the opportunity on Title 30—a little-known federal statute from the 1800s that allowed Americans to claim rights to public lands, which were often rich in mineral deposits. 'Back then, anyone could make a claim… pay $2 to $5 per acre… and do a minimal amount of work'. The framework still exists—and Rickards believes it may quietly be resurfacing to address modern strategic needs without requiring congressional debate. Technology May Be the Catalyst Rickards believes a convergence of technology and geopolitics is making this moment different: The use of AI mapping tools to identify previously unreachable mineral deposits The Pentagon's direct involvement in securing U.S. rare-earth supply chains Escalating foreign control over strategic mineral exports 'We have truly massive mineral wealth here. It's not hard to extract. We know where it is. And how to get it' About Jim Rickards Jim Rickards is a former advisor to the CIA, Pentagon, White House, and Treasury. His work has guided U.S. leadership during global crises including the Iran Hostage Situation and the 2008 financial collapse. He is the editor of Strategic Intelligence , a monthly report on national security, macroeconomics, and resource policy. Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same. Ahmedabad Plane Crash GlobeNewswire provides press release distribution services globally, with substantial operations in North America and Europe.
Business Upturn
5 hours ago
- Business Upturn
Perseus Mining June Quarter Report
By GlobeNewswire Published on July 28, 2025, 03:40 IST Perth, July 28, 2025 (GLOBE NEWSWIRE) — JUNE 2025 QUARTER REPORT Continued strong performance of Perseus Mining's operations grows cash & bullion balance to US$827 million PERTH, Western Australia/July 28, 2025/Perseus Mining Limited ('Perseus' or the 'Company') (TSX & ASX: PRU) reports on its activities for the three months' period ended June 30, 2024 (the 'Quarter'). Below is a summary of the release. The full report is available at and Key operating indicators and highlights for the June 2025 quarter (Q4 FY25) include: PERFORMANCE INDICATOR UNIT MARCH 2025 QUARTER JUNE 2025 QUARTER JUNE 2025 HALF YEAR 2025 FINANCIAL YEAR Gold recovered Ounces 121,605 121,237 242,843 496,551 Gold poured Ounces 122,915 119,868 242,782 495,984 Production Cost US$/ounce 977 1,038 1,008 980 All-In Site Cost (AISC) US$/ounce 1,209 1,417 1,313 1,235 Gold sales Ounces 117,585 131,242 248,826 494,343 Average sales price US$/ounce 2,462 2,977 2,734 2,543 Notional Cashflow US$ million 152 189 345 650 Record 12-month rolling average Total Recordable Injury Frequency Rate (TRIFR) of 0.60 is well below industry average. is well below industry average. Quarterly gold production of 121,237 ounces at a weighted average AISC of US$1,417 per ounce enabled Perseus to achieve production guidance and better cost guidance for June 2025 half year (2H FY25) and 2025 financial year (FY25) . at a weighted average enabled Perseus to for June 2025 half year (2H FY25) and 2025 financial year (FY25) Average gold sales of 131,242 ounces with a weighted average gold sales price of US$2,977 per ounce. with a weighted average Average cash margin of US$1,560 per ounce of gold produced, giving notional operating cashflow of US$189 million. of gold produced, giving Perseus's gold production and AISC outlook for the next 5 years includes average gold production of 515,000 – 535,000 ounces per year, at an average AISC of US$1,400 – US$1,500 per ounce . includes at an average . For the 2026 financial year ( FY26 ), gold production guidance is 400,000 – 440,000 ounces while AISC guidance is US$1,460 – 1,620 per ounce , representing a temporary dip in the longer-term outlook for the Company. ), is while is , representing a temporary dip in the longer-term outlook for the Company. A Final Investment Decision (FID) was taken during the quarter to develop the Nyanzaga Gold Project (NGP). Site works are accelerating and are on-budget and on schedule, consistent with the target of first gold production in January 2027. was taken during the quarter to develop the Site works are accelerating and are on-budget and on schedule, consistent with the target of first gold production in January 2027. Outstanding infill drilling results at NGP have Perseus on target for a Mineral Resource and Ore Reserve upgrade in Q3 FY26 resulting in a possible mine life extension. have Perseus on target for a Mineral Resource and Ore Reserve upgrade in Q3 FY26 resulting in a possible mine life extension. Available cash and bullion of US$827 million, plus liquid listed securities of US$118 million , notwithstanding significant payments associated with development of NGP, corporate tax, dividends and share buy-back payments. plus liquid , notwithstanding significant payments associated with development of NGP, corporate tax, dividends and share buy-back payments. Zero debt and available undrawn debt capacity of US$300 million at quarter-end. and available at quarter-end. Perseus's A$100 million buy-back of its shares continued between blackout periods during the quarter and is currently ~73% complete with 22,995,853 shares purchased and subsequently cancelled. GROUP GOLD PRODUCTION AND COST GUIDANCE Group gold production and AISC market guidance for FY26 is as follows: Table 10: Production and AISC Guidance PARAMETER UNITS 2026 FINANCIAL YEAR FORECAST Yaouré Gold Mine Production Ounces 168,000 – 184,000 All-in Site Cost USD per ounce $1,500 – $1,660 Edikan Gold Mine Production Ounces 154,000 – 169,000 All-in Site Cost USD per ounce $1,420 – $1,570 Sissingué Gold Mine Production Ounces 78,000 – 87,000 All-in Site Cost USD per ounce $1,470 – $1,620 PERSEUS GROUP Production Ounces 400,000 – 440,000 All-in Site Cost USD per ounce $1,460 – $1,620 The rise relative to prior periods in Perseus's guided AISC in FY25 as noted above can be attributed to a range of factors which have been considered in forecasting future operating costs, including an assumed gold price of US$2,700 per ounce for the period. A trend of rising costs is evident in the global gold sector, including in West Africa, driven by a range of factors, not the least of which is a steady increase in royalties and indirect charges payable to host governments (and others) which are a function of prevailing gold prices. In other words, as the price of gold rises, so too do expectations by host governments and host communities of an increasing share of the higher gold prices. This occurs in the form of higher royalty and gold price linked indirect charges by governments as well as an increase in the cost of land access and contributions to community assistance funds, demanded by host communities. Other factors that impact Perseus's operating costs include the rising cost of wages, freight costs and therefore consumables and the fact that in some operations, as they mature, haul distances and elevations increase and facilities such as tailings dams require expansion. In addition, forecast costs are impacted by site specific factors outside of Perseus's control such as at Yaouré, where an expected interruption is expected to the availability of power from the Ivorian power grid in H1 FY26 caused by planned maintenance of power stations that contribute power to the grid. It has been assumed that Perseus will be required to make significantly more use of its standby generators during this period which operate at a cost that is materially above grid power costs. SEptember 2025 QUARTER EVENTS & ANNOUNCEMENTS 22 July – Resource Definition Drilling Update for Nyanzaga Gold Project 28 July – June 2025 Quarterly Report & Webinar 27 August – Annual Mineral Resources and Ore Reserves Update 28 August – Financial Year 2024 Annual Report & Webinar 14-17 September – Mining Forum Americas Competent Person Statement All production targets referred to in this release are underpinned by estimated Ore Reserves which have been prepared by competent persons in accordance with the requirements of the JORC Code. Edikan The information in this release that relates to the Open Pit and Underground Mineral Resources and Ore Reserve at Edikan was updated by the Company in a market announcement 'Perseus Mining updates Mineral Resources and Ore Reserves' released on 21August 2024. The Company confirms that all material assumptions underpinning those estimates and the production targets, or the forecast financial information derived therefrom, in that market release continue to apply and have not materially changed. The Company further confirms that material assumptions underpinning the estimates of Ore Reserves described in 'Technical Report — Edikan Gold Mine, Ghana' dated 7 April 2022 continue to apply. Sissingué, Fimbiasso and Bagoé The information in this release that relates to the Mineral Resources and Ore Reserve at the Sissingué complex was updated by the Company in a market announcement 'Perseus Mining updates Mineral Resources and Ore Reserves' released on 21 August 2024. The Company confirms that all material assumptions underpinning those estimates and the production targets, or the forecast financial information derived therefrom, in that market release continue to apply and have not materially changed. The Company further confirms that material assumptions underpinning the estimates of Ore Reserves described in 'Technical Report — Sissingué Gold Project, Côte d'Ivoire' dated 29 May 2015 continue to apply. Yaouré The information in this release that relates to the Open Pit and Underground Mineral Resources and Ore Reserve at Yaouré was updated by the Company in a market announcement 'Perseus Mining updates Mineral Resources and Ore Reserves' released on 21 August 2024. The Company confirms that all material assumptions underpinning those estimates and the production targets, or the forecast financial information derived therefrom, in that market release continue to apply and have not materially changed. The Company further confirms that material assumptions underpinning the estimates of Ore Reserves described in 'Technical Report — Yaouré Gold Project, Côte d'Ivoire' dated 19 December 2023 continue to apply. Nyanzaga Gold Project The information in this report that relates to the Mineral Resources and Ore Reserve at Nyanzaga was updated by the Company in a market announcement 'Perseus Mining proceeds with development of the Nyanzaga Gold Project' released on 28 April 2025. The Company confirms that all material assumptions underpinning those estimates and the production targets, or the forecast financial information derived therefrom, in that market release continue to apply and have not materially changed. The Company further confirms that material assumptions underpinning the estimates of Ore Reserves described in 'Technical Report — Nyanzaga Gold Project' dated 10 June 2025 continue to apply. The information in this report relating to Nyanzaga exploration results was first reported by the Company in compliance with the JORC Code 2012 and NI43-101 in a market update 'Perseus Mining Delivers Encouraging Drilling Results from its Current Drill Program at the Nyanzaga Gold Project' released on 22 July 2025. The Company confirms that it is not aware of any new information or data that materially affect the information in that market release. Meyas Sand Gold Project The information in this report that relates to the mineral resources and probable reserves of the Meyas Sand Gold Project was first reported by the Company in a market announcement 'Perseus Enters Into Agreement to Acquire Orca Gold Inc.' released on 28 February 2022. The Company confirms it is not in possession of any new information or data relating to those estimates that materially impacts of the reliability of the estimate of the Company's ability to verify the estimate as a mineral resource or ore reserve in accordance with Appendix 5A (JORC Code) and the information in that original market release continues to apply and have not materially changed. These estimates are prepared in accordance with Canadian National Instrument 43-101 standards and have not been reported in accordance with the JORC Code. A competent person has not done sufficient work to classify the resource in accordance with the JORC Code and it is uncertain that following evaluation and/or further exploration work that the estimate will be able to be reported as a mineral resource or ore reserve in accordance with the JORC Code. This release and all technical information regarding Orca's NI 43-101 have been reviewed and approved by Adrian Ralph, a Qualified Person for the purposes of NI 43-101. Caution Regarding Forward Looking Information: This report contains forward-looking information which is based on the assumptions, estimates, analysis and opinions of management made in light of its experience and its perception of trends, current conditions and expected developments, as well as other factors that management of the Company believes to be relevant and reasonable in the circumstances at the date that such statements are made, but which may prove to be incorrect. Assumptions have been made by the Company regarding, among other things: the price of gold, continuing commercial production at the Yaouré Gold Mine, the Edikan Gold Mine and the Sissingué Gold Mine without any major disruption, development of a mine at Nyanzaga, the receipt of required governmental approvals, the accuracy of capital and operating cost estimates, the ability of the Company to operate in a safe, efficient and effective manner and the ability of the Company to obtain financing as and when required and on reasonable terms. Readers are cautioned that the foregoing list is not exhaustive of all factors and assumptions which may have been used by the Company. Although management believes that the assumptions made by the Company and the expectations represented by such information are reasonable, there can be no assurance that the forward-looking information will prove to be accurate. Forward-looking information involves known and unknown risks, uncertainties, and other factors which may cause the actual results, performance or achievements of the Company to be materially different from any anticipated future results, performance or achievements expressed or implied by such forward-looking information. Such factors include, among others, the actual market price of gold, the actual results of current exploration, the actual results of future exploration, changes in project parameters as plans continue to be evaluated, as well as those factors disclosed in the Company's publicly filed documents. Readers should not place undue reliance on forward-looking information. Perseus does not undertake to update any forward-looking information, except in accordance with applicable securities laws. This market announcement was authorised for release by the Board of Perseus Mining Limited. ASX/TSX CODE: PRU CAPITAL STRUCTURE: Ordinary shares: 1,353,991,309 Performance rights: 9,328,134 REGISTERED OFFICE: Level 2 437 Roberts Road Subiaco WA 6008 Telephone: +61 8 6144 1700 DIRECTORS: Rick Menell Non-Executive Chairman Jeff Quartermaine Managing Director & CEO Amber Banfield Non-Executive Director Elissa Cornelius Non-Executive Director Dan Lougher Non-Executive Director John McGloin Non-Executive Director James Rutherford Non-Executive Director CONTACTS: Jeff Quartermaine Managing Director & CEO [email protected] Stephen Forman Investor Relations +61 484 036 681 [email protected] Nathan Ryan Media +61 420 582 887 [email protected] Attachment TSX Release_Q4 FY25 Quarterly Report_Final Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same. Ahmedabad Plane Crash GlobeNewswire provides press release distribution services globally, with substantial operations in North America and Europe.
